Informal Advisory Group on the Availability and Affordability of Cancer Medicines

Report of the meeting 4 – 6 April 2018
Geneva, Switzerland
Contents

Acronyms and abbreviations 3
Executive summary 4
Milestones for developing the technical report 4
I. Background and objectives of the meeting 6
II. Outcome of discussions on interpreting the resolution and defining the scope of the technical report 7
III. Outcome of discussions on pricing approaches and their potential impact 8
IV. Summary of policy options proposed by experts 9
Annex: List of participants 13

Acronyms and abbreviations

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EML</td>
<td>Essential Medicines List</td>
</tr>
<tr>
<td>EMP</td>
<td>Essential Medicines and Health Products (WHO Department)</td>
</tr>
<tr>
<td>ERP</td>
<td>External reference pricing</td>
</tr>
<tr>
<td>HAI</td>
<td>Health Action International</td>
</tr>
<tr>
<td>HTA</td>
<td>Health technology assessment</td>
</tr>
<tr>
<td>IAU</td>
<td>Innovation, Access and Use (WHO Unit)</td>
</tr>
<tr>
<td>MND</td>
<td>Management of Noncommunicable Diseases (WHO Unit)</td>
</tr>
<tr>
<td>NVI</td>
<td>Noncommunicable Diseases, Disability, Violence and Injury Prevention (WHO Department)</td>
</tr>
<tr>
<td>TRIPS</td>
<td>Agreement on Trade-Related Aspects of Intellectual Property Rights</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
Executive summary

At the Seventieth World Health Assembly in 2017, World Health Organization (WHO) Member States adopted resolution WHA70.12, Cancer prevention and control in the context of an integrated approach, and WHO was requested to prepare a technical report on pricing approaches for cancer medicines for presentation to the Executive Board. An informal advisory group meeting was convened by WHO in April 2018 to obtain relevant input from experts nominated by all WHO Regional Offices. The consultation aimed to provide expert advice on the scope of the report, on the benefits and consequences of various pricing approaches for cancer medicines and on options for improving the availability and affordability of cancer medicines.

The advisory group agreed that the resolution is meaningful for countries across income levels, although specific issues faced will differ. It acknowledged that although the remit of the technical report is an analysis of pricing of cancer medicines, there is a need to set oncology spending in a broader context of cancer diagnosis and treatment. It is also clear that pricing strategies for cancer medicines need not necessarily differ from pricing of other medicines, although calls for access have led many countries to pilot cancer-specific pricing policies.

Experts discussed policy and economic objectives related to pricing of cancer medicines, as well as price regulation and procurement policies across countries. It was agreed that different health systems and production capacities of countries must be considered in developing the technical report. Key issues raised also concerned countries’ pricing policies, including the need to develop and enforce policies for equitable access, sustainable supply and procurement.

Options were proposed for national and regional levels to strengthen pricing approaches and policies, and for building the capacity to implement actions across the pharmaceutical value chain.

Suggestions for improving the availability and affordability of cancer medicines include:

- Strengthening pricing policies at the national and regional levels
  - Improving the consistency of policies across health and other sectors;
  - Designing of differential pricing sensitive to health systems’ ability to pay;
  - Enhancing system ability to review and adjust prices, and divest if required;
  - Creating competition among substitutable cancer medicines, with respect to price, quality and supply.
- Improving the efficiency of expenditure on cancer medicines
  - Prioritizing the selection of medicines with high(er) clinical value with reference to existing guidance and country context;
  - Considering the costs of the model of care as part of the pricing approach;
  - Considering managed entry agreements for expenditure control in specific cases such as medicines with anticipated high expenditure and uncertain longer-term clinical benefits;
  - Avoiding the use or establishment of funds earmarked for the provision of cancer medicines, unless such funds are essential for access to medicines with proven clinical and economic value;
  - Implementing pre-authorization as a measure to ensure appropriate use.
• Improving the transparency of pricing approaches and prices of cancer medicines
  o Disclosing the net transaction prices of cancer medicines to relevant stakeholders;
  o Disclosing and controlling prices along the supply chain;
  o Reporting the costs of research, development and production, including any public sources of funding;
  o Communicating pricing and reimbursement decisions to the public when appropriate, to foster a common understanding and promote accountability.

• Promoting cross-sector and cross-border collaboration for information sharing, regulation, and procurement
  o Sharing information on medicine prices and technical assessments;
  o Harmonizing regulatory requirements for biosimilar medicines to ensure safety and quality, and to promote competition;
  o Streamlining cross-border regulatory requirements and supply management of medicines in shortage;
  o Pooling sub-national, national and regional resources for joint negotiation and procurement;
  o Applying TRIPS flexibilities for patented medicines where appropriate.

• Managing factors that would influence demand for medicines
  o Removing financial / non-financial incentives for prescribing cancer medicines of limited clinical value;
  o Restricting promotional activities of cancer medicines to clinicians and the public;
  o Correcting any misperception of inferior quality of generic or biosimilar medicines;
  o Implementing regulatory measures upon identification of substandard and falsified medicines.

• Realignment of incentives for research and development
  o Incentivizing research for cancers that affect smaller populations;
  o Focusing on health service research to improve system efficiencies, rational use of medicines and packages of care.

The feasibility of these preliminary recommendations is under assessment, and an updated set of options to enhance the affordability and accessibility of cancer medicines will be included in the technical report to the Executive Board at its 144th session.

Milestones for developing the technical report

• Experts to provide ongoing additional data and information to support technical analyses and case studies.
• Member State and stakeholder discussions to be held on the technical report in the third quarter of 2018.
• Technical report to be submitted to the Executive Board by October 2018 for discussion in January 2019.
I. Background and objectives of the consultation

At the Seventieth World Health Assembly in 2017, Member States adopted resolution WHA70.12, Cancer prevention and control in the context of an integrated approach. As part of this resolution, the Director-General was requested “to prepare a comprehensive technical report to the Executive Board at its 144th session that examines pricing approaches, including transparency, and their impact on availability and affordability of medicines for the prevention and treatment of cancer, including any evidence of the benefits or unintended negative consequences, as well as incentives for investment in research and development on cancer and innovation of these measures, as well as the relationship between inputs throughout the value chain and price setting, financing gaps for research and development on cancer, and options that might enhance the affordability and accessibility of these medicines”.

An informal advisory group was appointed based on the Terms of Reference previously developed and approved by the Assistant Director General of Medicines, Vaccines and Pharmaceuticals. To ensure the representation of Member States of various income levels and contexts, nominations for experts with experience in cancer care and/or cancer medicines research and development, pricing or supply chain were solicited from all WHO regions. The final composition of the group respected gender balance, regional representation, diversity of technical competence and expertise.

The group met from 4 to 6 April 2018 to provide expert advice on:

- the scope of the report, analytical feasibility and case studies;
- the benefits and consequences of various pricing approaches for cancer medicines;
- options for improving availability and affordability of cancer medicines.

A separate group, the Cancer Medicines Working Group (CMWG) met 22-23 March 2018 to review selected cancer medicines for the Essential Medicines List (EML). The aim of that meeting was to establish clear principles that can guide the selection of optimal medicines to be considered for EML inclusion and review the available tools and thresholds for clinical and public health relevance of a medicine. The CMWG was established at the recommendation of the 2017 meeting of the WHO Expert Committee on Selection and Use of Essential Medicines, where the potential to identify thresholds of benefits for cancer medicines was discussed. A summary of that meeting is published as a companion to this report.
II. Outcomes of discussions on interpreting the resolution and defining the scope of the technical report

- **The resolution is relevant to all countries.** It was agreed that the resolution is relevant for countries across all income levels, although specific issues faced will differ. Health care expenditure on cancer medicines can be significant. Countries with a high proportion of out-of-pocket expenditure experience high rates of financial catastrophe and resulting poverty. Existing reimbursement schemes are often insufficient to minimize financial harm. Priorities must be set to ensure that public expenditure on cancer treatment is equitable and efficient.

- **The technical report needs to be positioned in a context broader than medicines.** The experts acknowledged that the remit of the technical report to the Executive Board is an analysis of pricing of medicines. However, oncology spending needs to be described in a broader context that includes diagnosis, surgery, radiotherapy, palliative care, and other interventions in addition to pharmacological treatment. While this may go beyond the scope of the informal consultation and technical report, experts requested that the report refer to the broader context and related WHO initiatives.

- **Quality of medicines is vital but beyond the scope of the technical report.** Experts expressed a fundamental concern on ensuring the quality of medicines. Nonetheless it was agreed the report should focus on pricing approaches for quality medicines. Any potential impact on the quality of medicines resulting from pricing should be raised.

- **Infrastructure, guidance and a competent workforce are essential.** Pricing policies must be considered in the context of adequate selection principles and affordable diagnostic approaches, along with a workforce that is competent to detect and manage cancer.

- **Approaches to pricing cancer medicines may differ from those for other medicines.** It was agreed that, in principle, cancer medicine pricing should not differ from pricing medicines for other diseases. On the other hand many countries have piloted pricing policies unique to cancer medicines. It would be useful for the technical report to examine whether such approaches have been successful or could appropriately serve as an indication for pricing of other medicines. Experts strongly advised that the principle of affordability should be held central.

- **The technical report must be relevant to policy makers, and feasible to implement.** The report should aim to help countries in the short term in addition to identifying longer-term strategies. It should address elements of access that include receiving the medicines at the right time and in the right doses.
III. Outcome of discussions on pricing approaches and potential impact

- Policy and economic objectives: Key policy issues identified during the consultation include cost containment, incentives for innovation, promotion of local production and the use of generics or biosimilars. Economic objectives cover sustainability of the pharmaceutical industry, encouraging competition, patent systems and competition law. More attention is needed to demand side policies in addition to value chain policies.

- Off-label prescribing: Because of its unique emotional power and calls for access, cancer care prompts political will to permit more off-label prescribing than many other specialties. However, in principle there are no differences in policy objectives for cancer medicines and medicines in general.

- Price regulation and procurement: A discussion of a variety of price regulation and procurement policies across countries led to agreement that the technical report must consider different health systems and production capacities of countries. Some countries may not provide strategic procurement resources to undertake good procurement practices. Health systems should enhance the ability to review and adjust prices, and divestment if required, based on routine monitoring as well as on evaluation of evidence on utilization, clinical value, prices, quality and supply.

- Pricing policies in countries: Countries are urged to create and enforce policies for equitable access, sustainable supply and procurement. It is difficult to establish how industry sets prices, since there are variable markets and information asymmetry. The price setting for patented products is different from generic products. Some prices of patented medicines are confidential and therefore non-transparent, though there is some indication that policymakers are becoming increasingly aware of the impact and consequences of policies that rely on external reference pricing (ERP, see below).

- Controlling costs: Launch prices can be high, although mechanisms such as health technology assessment (HTA), ERP, and additional negotiation may result in substantial discounts. The experts recommended that the report should discuss the role of negotiation in obtaining affordable prices for cancer medicines and describe the relative success across countries. Proactive engagement by governments in determining initial pricing for a product and improving negotiation skills could be initial steps in controlling spending. There is a lack of knowledge about the clinical benefits and risks of many newer cancer medicines, particularly at launch when initial pricing and coverage is determined. It is important to be able to identify patients who will benefit from certain medicines to keep the costs under control. Newer generation medicines that extend longevity are associated with increased costs because of longer treatment courses and higher unit costs.
• Differential pricing: The technical report should address the use and relative merits of differential pricing and ERP in countries, while not duplicating efforts of previous analyses on the subject. ERP was not considered to result in equitable pricing. There are elements of differential pricing that are sensitive to the differences in health system’s ability to pay, and discussion revolved around how such a system could be established. Concerns were raised regarding the principle of affordability of special cancer reimbursement schemes in those countries that are willing to pay. It was suggested that countries that have achieved lower prices might face issues of supply, as products are frequently prioritized for markets with higher financial returns.

• Managed entry agreements: Experts pointed to a lack of concurrence on the scope and structured processes of managed entry agreements implemented to date. While these should not become the norm, managed entry agreements could be useful in exceptional cases for expenditure control, for example in the case of medicines with anticipated high expenditure and uncertain longer-term clinical benefits. The utility of managed entry agreements must be weighed against the administrative burden and appropriate contract terms. Questions to explore include the impact of such policies on evidence generation, and their feasibility in low-income countries.

• Cross-border collaboration: The technical report should discuss the consequences of cross-border collaboration, for example pooled procurement, and the benefits of national or regional procurement compared to procurement per hospital. In many countries, fragmented health care systems lead to different payers and to sectors with different responsibilities. This in turn risks increasing prices and weakening the purchasing power of buyers.

• Patient access initiatives: Several unique issues were raised for consideration in the technical report, in particular related to government and industry initiatives for increasing patient access. Specifically, experts pointed to the challenges created when products are provided to patients prior to national assessment or outside of the regular reimbursement system. These create pressure on the country to continue access and they support a lack of transparency. Although the potential benefits of these initiatives were acknowledged, it was suggested that policies to improve consistency and transparency should be explored. This could be as simple as continuing access to these programmes for the lifespan of the patient or until the disease is controlled. Further information is also needed about the impact of such initiatives on health systems and outcomes.

• Competition: Leveraging competition on price and supply among cancer medicines, including patented medicines that produce similar outcomes, was suggested. For products that have gone off-patent, any misperception of inferior quality of generic or biosimilar medicines should be corrected. National regulatory requirements for biosimilars could be streamlined to promote competition and to avoid the duplication of clinical trials in different national settings.

• Generic medicines: Prescribers should be encouraged to prescribe generic medicines when appropriate; this could be done by offering financial incentives. Financial and non-financial incentives for prescribing cancer medicines of limited clinical value should be removed. Promoting cancer medicines to clinicians and the public must be restricted. Pre-authorization by third party payers might be implemented as a measure to ensure the appropriate use of cancer medicines.
• Transparency: Sustainable pricing, access and health care systems must be based on transparency, although it was noted that definitions of the term are varied and inconsistent. Areas needing clarification include the specific information to be made transparent, the relevant stakeholders who need access to that information, and the objectives and outcomes of such a transparent system. For example, the net transaction prices of cancer medicines should be disclosed to relevant stakeholders, but perhaps not to the public. On the other hand, pricing and reimbursement decisions, their impact and rationale should be communicated to the public when appropriate, to foster a common understanding and promote accountability. The technical report should analyze the potential consequences of making (actual) prices publicly available.

• Research and development costs: Transparency is also needed regarding public spending on, and public sources of funding for, research and development. A single medicine may be used to treat multiple stages of disease or for different indications, making it difficult to appropriately allocate research and development costs. The technical report should discuss the influences of these costs, comparators, competitors and consumers on pricing of medicines.

• Paediatric oncology: Cancer medicines for children are faced with unique challenges concerning research and development, production, formulation, pricing, availability, and access, all of which should be highlighted in the technical report. Formulations for appropriate dosing are rare, and there is a significant amount of off-label use in addition to problems with prices and efficient use of medicines. Because paediatric medicines do not have a high return on investment, other products may be prioritized, exacerbating the problem of availability.

• Balancing public health and industry needs: It was perceived that industry-funded research and development focuses on new medicines for specific disease subtypes rather than on repurposing existing therapies, or on developing oral formulations. This issue should be highlighted in the report. Financing gaps in research and development for head-to-head trials could promote competition or (dis)investment. Increased attention is also needed on health services research to improve system efficiencies, specifically product wastage, rational use and packages of care. There is a dominance of research on certain cancer types, indicating a need to incentivize research for rare and pediatric cancers.

• Voluntary licensing and TRIPS: To facilitate access to affordable treatment, it was recommended to expand the use of voluntary licensing and the mandate of the Medicines Patent Pool, as well as taking advantage of the flexibilities offered in the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement.
IV. Summary of policy options proposed

Policy options cover strengthening of pricing policies at the national and regional levels, improving the efficiency of expenditure on cancer medicines, improving price transparency of cancer medicines, promoting cross-sector and cross-border collaboration for information sharing, regulation, and procurement, managing factors that would influence demand for medicines and realignment of incentives for research and development.

- Pricing approaches and policies need to be strengthened along the value chain at national and regional levels. The consistency of policies should be ensured across public and private health sectors as well as with non-health sectors (for example, trade).

- Mechanisms should be explored for designing differential pricing that is sensitive to the health system’s ability to pay and that takes into consideration the costs of goods. The design of such a system should be driven by country and regional needs, rather than reactive to market forces.

- The ability of health systems to review and adjust prices should be enhanced, and systems should be able to divest if required. Such decisions should be based on routine monitoring and evaluation of evidence on utilization, clinical value, prices, quality and supply.

- Price increases without explicit justification should be prohibited. It could be useful to leverage competition on price and supply among cancer medicines with suitable substitutes, including patented medicines that produce similar outcomes.

- Various options for more efficient budgetary management were suggested. The selection of medicines should give priority to those with high(er) clinical value based on existing guidance (such as the WHO Essential Medicines List) and the country context (for example the disease burden, health system capacity and HTA). The costs of the broader treatment paradigm, including but not limited to medicines should be included as part of the pricing approach.

- Managed entry agreements should be considered for expenditure control, particularly in the case of medicines with anticipated high expenditure and uncertain longer-term clinical benefits.

- The use or establishment of funds earmarked for the provision of cancer medicines should be avoided, unless such funds are essential for access to medicines with proven clinical and economic value. Implementation of pre-authorization was suggested as a measure to ensure appropriate use of cancer medicines.

- Various options were suggested for promoting cross-sector and cross-border collaboration for information sharing, regulatory measures, and procurement. Possibilities include a) sharing information on medicine prices and technical assessments (for example horizon scanning and HTA) and b) encouraging regulatory requirements for biosimilar medicines to ensure safety and quality, to stimulate competition and to avoid duplication of clinical trials in different national settings. Pooling efforts for negotiation and procurement, particularly for patented medicines, should be put in place where appropriate and practicable.
• The use of voluntary licensing and the mandate of the Medicines Patent Pool should be expanded, and the flexibilities of the TRIPS agreement be implemented to facilitate access to affordable treatment when necessary.

• Transparency of pricing approaches and prices of cancer medicines needs to be improved. Relevant stakeholders should disclose the net prices of cancer medicines, although full public transparency may or may not be appropriate.

• Prices along the value chain have to be controlled including mark-ups. Costs of research, development and production, including any public sources of funding, should be reported to the public when appropriate. This will help foster a common understanding and promote accountability.

• Factors that may result in inappropriate utilization of medicines have to be managed. Financial and non-financial incentives for prescribing cancer medicines should be removed, and promotional activities of cancer medicines to clinicians and the public should be restricted. These actions will help correct misperceptions on the quality of generic or biosimilar medicines. National regulatory measures also need to be implemented upon identification of substandard and falsified medicines.

• Incentives for research and development on cancer treatment should be realigned and updated. Incentives are particularly needed for research on cancers affecting smaller populations (rare cancers, paediatric cancers and formulations for pediatric oncology), and for health service research to improve system efficiencies (rational use and packages of care).
Annex: List of participants

**Expert advisers**

Moses Chisale  
Central Medical Stores Trust, Malawi

Avram Denburg  
University of Toronto, Canada

Gihan Hamdy El-Sisi  
Ministry of Health and Population, Egypt

Saed Jaddoua  
King Hussein Cancer Center, Jordan

Jin Soo Lee  
Korea National Cancer Center (Emeritus)

Miriam Naarendorp  
Ministry of Health, Suriname

Kamaruzaman bin Saleh  
Ministry of Health, Malaysia

Sakthivel Selvaraj  
Public Health Foundation of India

Netnaps Suchonwanich  
National Health Security Office (Emeritus), Thailand

Fatima Suleman (Chair)  
University of KwaZulu-Natal, South Africa

Richard Sullivan  
Kings Institute of Cancer Policy, United Kingdom

Fola Tayo  
Caleb University, Nigeria

Sabine Vogler  
Austrian Public Health Institute

All experts completed the Declaration of Interest form. The Secretariat considers that none of the declarations constitute a conflict with the objectives of the group.

**Secretariat**

Suzanne Hill  
Director, EMP Department

Sarah Garner  
Coordinator, EMP/IAU

Hanne Bak Pedersen  
Regional Advisor, WHO Regional Office for Europe

Andrew Rintoul  
EMP/IAU

Nicola Magrini  
EMP/IAU

Lorenzo Moja  
EMP/IAU

Kiu Tay  
EMP/IAU

Allison Colbert  
EMP/IAU

Swathi Iyengar  
EMP/IAU

Anne Hendriks  
EMP/IAU

André Ilbawi  
NVI/MND

Dario Trapani  
NVI/MND